| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73e0d5808f34f512649e277bd216a344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a910d33c239980f3a705e312c5bad6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-501
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-433 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B59-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 |
| filingDate |
2018-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c01403d3f7b44e489f94863d29f3cbab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea1d9a707f603a193eb98e4c787087c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03457e56cba1c112762f7696be773d6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bd86502d35afbfc8079ef8262a79463
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3946dfc79e6d9cffde4f0e13018a3dcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b98fa6bfe62a64a4876a9b82e0642df |
| publicationDate |
2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10294221-B2 |
| titleOfInvention |
1, 3, 4-thiadiazole compounds and their use in treating cancer |
| abstract |
The specification relates to compounds of Formula (I): n nand pharmaceutically acceptable salts thereof, where Q, R, R 1 and R 2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent GLS1 mediated disease, including cancer. The specification further relates to crystalline forms of compounds of Formula (I) and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating GLS1 kinase mediated disease, including cancer, using such compounds and salts. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10981904-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10577354-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11753405-B2 |
| priorityDate |
2014-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |